An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A
- Registration Number
- NCT01608659
- Lead Sponsor
- Allergan
- Brief Summary
This is a retrospective chart review to evaluate treatment patterns of botulinum toxin Type A for the treatment of facial lines.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 110
Inclusion Criteria
- Previously treated for glabellar lines (hyperfunctional facial lines) with botulinum toxin Type A preparation
- Received 2 treatment cycles wtih botulinum toxin Type A (BOTOX®) prior to at least 1 treatment with botulinum toxin Type A (Xeomin®)
Exclusion Criteria
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description botulinum toxin Type A botulinum toxin Type A Previous treatment with botulinum toxin Type A for treatment of facial lines
- Primary Outcome Measures
Name Time Method Average Total Dose Per Treatment Period 24 Months Average total dose per treatment period was defined as total treatment dose plus total touch-up dose plus total follow-up dose.
- Secondary Outcome Measures
Name Time Method Percent of Subjects Reporting Satisfaction With Treatment Effects 24 Months Percent of subjects reporting satisfaction with treatment effects per chart notes.
Inter-Injection Interval Duration of Each Treatment Period 24 Months Inter-injection interval duration of each treatment period. Duration is defined as the number of days of an injection cycle.